Tarek Baati | Nanobiotechnology | Best Scholar Award

Posted on by ScienceFather

Dr. Tarek Baati | Nanobiotechnology | Best Scholar Award

Dr. Tarek Baati, Institut National de Recherche et d’Ananlyse Physicochimique, Tunisia

Dr. Tarek Baati is a seasoned toxicologist and Senior Lecturer based in Tunisia. With an HDR from the Institut SupĆ©rieur de biotechnologie de Monastir in 2022, his extensive educational background includes a PhD in Toxicology from the University Paris11 in 2009. Dr. Baati has diverse expertise, from analytical chromatography to animal surgery techniques acquired during his formations in France. Proficient in languages such as French, English, and Arabic, he excels in in vitro, ex-vivo, and in vivo testing, tumor model development, and nanoparticle safety studies. Dr. Baati actively contributes to research, supervising students, and serving as a reviewer for Q1 Journals. His passion extends beyond science, embracing football, chess, photography, and DIY projects. šŸ§ŖšŸ“ššŸ”¬

šŸŽ“ Education & Qualifications:

2022: HDR (Institut SupƩrieur de Biotechnologie de Monastir). 2013: Analytical Chromatography and Separation Techniques, IUT- Orsay (France). 2012: Animal Surgery Techniques (Marseille, France). 2011: Transmission Electron Microscopy Techniques (Orsay, France). 2009: PhD in Toxicology, Faculty of Pharmacy, University Paris11. 2005: Master in Biology and Health, Institut SupƩrieur de Biotechnologie de Monastir.

šŸ–„ļø Informatics:

Proficient in Pack Office 2010, social networks, HPLC software (Empower, Chromquest), Image processing: ImageJ, Corel 12, Statistics (SPSS11)

šŸ”¬ Technical Skills:

Conducts in vitro, ex-vivo, and in vivo tests. Cell line culture and IC50 analysis. Migration tests in transwell chambers and immuno-fluorescence. Development of tumor models in nude mice. Study of nanoparticles safety and biodistribution. Application of nanoparticles for drug delivery and detoxification. Analysis of histopathological examination of organs. Extraction, purification, and testing of natural substances. Development and validation of analytical methods by HPLC-PDA. Assessment of biochemical markers. Supervision of Ph.D. and Master degree students. Reviewer for several Q1 Journals. Organization and participation in scientific meetings. Teaching toxicology and biochemistry.

šŸ… Various:

Member of the Tunisian Association of Toxicology, Faculty of Pharmacy of Monastir. Interests: Football, Chess, Photography, DIY.

Professional Profiles:

The impact of her research is evident in citation metrics and indices from Google Scholar:

  • Cited by: All ā€“ 10271.
  • Citations ā€“ 10271.
  • h-index ā€“ 20.
  • Documents ā€“ 40.

A prolific researcher making meaningful contributions to the academic world!

šŸ”¬ Research Focus:

Dr. Tarek Baati’s research primarily focuses on the development and application of porous metalā€“organic-framework (MOF) nanoscale carriers for drug delivery and imaging, as evidenced by his extensive citations in the field. His work spans various aspects, including the use of MOFs in biomedicine, in-depth analysis of the in vivo toxicity of porous iron (III) MOFs, and the design of biodegradable therapeutic MOFs for delivering bioactive molecules. Additionally, he explores innovative approaches such as enhancing anti-HIV activity through MOF nanoparticles. Dr. Baati’s contributions also extend to studying the effects of nanomaterials on lifespan and investigating preventive measures against chromosome aberrations induced by certain compounds. šŸ§ŖšŸ”¬šŸŒ

Publications Top Note:

MĆ³nica L Fanarraga | Nanobiotechnology | Excellence in Research

Posted on by ScienceFather

Prof Dr. MĆ³nica L Fanarraga | Nanobiotechnology | Excellence in Research

Prof Dr. MĆ³nica L Fanarraga, Universidad de Catabria, Spain

šŸ‘©ā€šŸ”¬ Prof. Dr. MĆ³nica L. FanarragašŸŽ“ An esteemed researcher and Professor at the University of Cantabria, Spain, Dr. MĆ³nica L. Fanarraga is a trailblazer in nanomedicine. With dual PhDs in Biology and Medicine/Surgery, she founded the “Nanomedicine” research group at IDIVAL Institute. Over 40 competitive projects and 70 JCR publications showcase her impact. Recognized with the “Best Researcher Award” in 2022, she mentors researchers and champions innovation. Dr. Fanarraga’s recent projects secured substantial funding, affirming her dedication to cutting-edge nanomedicine research. Her contributions extend to patents, including groundbreaking work on silica nanoparticles, emphasizing her commitment to advancing scientific knowledge for over 30 years. šŸŒšŸ”¬šŸ†

šŸ« Education & Experience:

šŸŽ“ Degrees in Veterinary Medicine (1989). šŸ“š Dual PhDs in Biology (1993) and Medicine and Surgery (1999). šŸ§Ŗ Founder of the “Nanomedicine” research group at IDIVAL Institute, Santander, Spain. šŸ‘©ā€šŸ« Current Professor at the University of Cantabria. šŸ† “Best Researcher Award” from Fenin (Spanish Platform for Innovation in Health Technology, 2022).

šŸ”¬ Academic Achievements:

šŸŒ Spearheaded over 40 competitive research projects in nanobiotechnology. šŸ“š Published 70+ JCR publications in esteemed journals. šŸ“ Principal Investigator for articles in journals like Adv. Healthc. Mat., J.Nanobiotech, Angewandte Chem, Nature, ACS Nano. šŸ… Secured 5 patents in the field of nanomedicine. šŸŽ“ Mentored 10 postdoctoral researchers and supervised 14 defended doctoral theses. šŸ… 6 theses received the “Extraordinary Prize,” 2 awarded the “Juan MĀŖ ParĆ©s” Prize.

šŸ’” Contributions to Research & Development:

šŸŒŸ Led successful projects, including TED2021-129248B-I00, securing ā‚¬426,650 in funding. šŸ’° Secured funding for various Innovation projects, ranging from ā‚¬15,000 to ā‚¬56,100. šŸŒ Actively involved in mentoring young scientists for national and international postdoctoral initiatives. šŸ† Key role in Marie Curie H2020-MSCA-IF-2019 project (ā‚¬62,220) and Horizon-MSCA-Doctoral Networks 2021 project (ā‚¬250,000).

šŸ§Ŗ Innovations in Nanomedicine:

šŸ§¬ Pioneering work on silica nanoparticles for nucleic acid encapsulation (2021). šŸ”„ Innovative approaches in protein (2017) and carbon nanotube conjugation of nanomaterials (2017). šŸ§  Contributions to neurodegenerative disease research and advancements in gene transfer methods showcase continuous efforts in pushing scientific boundaries over 30 years.

Professional Profiles:

The impact of her research is evident in citation metrics and indices from Google Scholar:

  • Cited by: All ā€“ 2906.
  • Citations ā€“ 2906.
  • h-index ā€“ 29.
  • Documents ā€“ 100.

A prolific researcher making meaningful contributions to the academic world!

šŸ”¬ Research Focus:

šŸ” Prof Dr. Fanarraga has made significant contributions in the fields of cell biology and nanomedicine. Her pioneering work encompasses critical areas such as organelle transport, microtubule dynamics, and controlled drug delivery systems. With a remarkable citation record, her impactful studies on dynactin’s role in bidirectional organelle transport (399 citations) and the uncoupling of hypomyelination and glial cell death (238 citations) showcase her expertise in cell biology. Additionally, her exploration of postchaperonin tubulin folding cofactors (163 citations) and their role in microtubule dynamics demonstrates a multifaceted approach to understanding cellular processes. Dr. Fanarraga’s diversified research extends to innovative applications, including magnetic hyperthermia-enhanced cell toxicity (125 citations) and the use of carbon nanotubes in mimicking microtubule properties (81 citations). Her extensive body of work reflects a commitment to advancing knowledge at the intersection of cellular biology and nanomedicine. šŸŒšŸ”¬

Publications Top Note:

Dr Sobia Abid | Nanobiotechnology | Best Researcher Award

Posted on by ScienceFather

Dr Sobia Abid: Nanobiotechnology: Best Researcher Award

Dr Sobia Abid, The islamia university of bahawalpur, Ā Pakistan

Ms. Sobia Abid has an impressive academic background, including a Bachelor of Science degree (BS) in 2016, a Master of Science degree (MS) in 2019, and a Doctor of Philosophy (PhD) in Zoology in 2023, all from the Islamia University of Bahawalpur. Her research interests span diverse fields such as fisheries, entomology, diversity, and nanotechnology. Notably, she has gained recognition for her scholarly contributions, with 20 publications in internationally recognized journals accredited by the Higher Education Commission (HEC) and an impact factor of 23.75.

With a remarkable track record of both teaching and research, Ms. Sobia Abid has accumulated 6 years of experience in academia. Furthermore, her dedication to mentoring and nurturing young scholars is evident in her supervision of 30 Bachelor of Science (BS) research students and 8 Master of Science (MS) research students. Ms. Sobia Abid’s unwavering commitment to advancing knowledge in the field of Zoology and her outstanding contributions to both academia and research make her an invaluable asset to any institution.

Honor and Awards:

Dr. Sobia Abid has garnered recognition and accolades for her notable contributions in various spheres. She was honored with a certificate for organizing the first virtual webinar on “International Biodiversity Day” at the international level in May 2021, showcasing her commitment to global environmental awareness. Additionally, she received a shield of appreciation for successfully organizing the first annual science models exhibition in December 2021, highlighting her dedication to promoting scientific inquiry and innovation. Dr. Abid was also awarded a shield and certificate for spearheading a community-based blood screening campaign with the development of a mobile application, showcasing her efforts in leveraging technology for healthcare advancements. Furthermore, her expertise in the field of fisheries was recognized with a shield and certificate of honor for her presentation at the Fish Feed and Feeding workshop at Fish Seed Hatchery, Bahawalpur, in 2020. Her organizational skills were acknowledged with a Certificate of Honor for her role as the organizer of the Department of Life Sciences at The Islamia University of Bahawalpur in 2015. Additionally, she showcased her literary talents by winning an essay writing competition at the district level in Bahawalpur in 2012, demonstrating her multifaceted capabilities and commitment to excellence across different domains.

Workshops, Webinars and trainings:

Dr. Sobia Abid’s dedication to professional development is evident through her extensive participation in various workshops, webinars, and training programs. She has continuously sought to enhance her skills and knowledge in research-related areas, showcasing a commitment to staying updated with the latest developments in her field. In 2022, she attended international webinars focusing on effective presentation skills for researchers and research synopsis writing, demonstrating her interest in refining her research communication abilities. Additionally, she engaged in hands-on training sessions on HPLC and permeation analysis at BZU Multan and participated in a national training workshop on ELISA-based diagnostics at the University of Agriculture, Faisalabad. Dr. Abid also attended several webinars addressing diverse topics such as author networks, the editorial process, COVID-19 pandemic impact, and healthy living for hepatitis prevention, showcasing her broad interest in research-related subjects. Furthermore, she has actively participated in workshops and training programs on bio-safety, biodiversity conservation, scientific writing, literature search, and reference management, indicating her comprehensive approach to professional development. Her attendance at international symposiums and workshops on desert ecosystem management highlights her engagement with broader environmental and ecological themes. Dr. Abid’s proactive approach to learning and skill development underscores her dedication to advancing her expertise in research and academia

Conferences:

Dr. Sobia Abid’s active participation in numerous national and international conferences reflects her deep engagement with the field of zoology and its evolving trends. In 2022, she attended the Zoological Emerging Scientific Trends conference, showcasing her commitment to staying abreast of the latest developments in zoological research. She also took part in the 40th Pakistan Congress of Zoology organized by Sindh Agriculture University in December 2021, demonstrating her involvement in prestigious academic gatherings. Dr. Abid’s attendance at the 39th and 38th Pakistan Congress of Zoology, as well as the 2nd International Conference of Applied Zoology, illustrates her consistent engagement with these platforms over the years, highlighting her dedication to advancing her knowledge and expertise in the field. Moreover, her participation in conferences addressing broader topics such as climate change, biodiversity, and zoonotic diseases underscores her interdisciplinary approach to zoological research, showcasing her interest in exploring diverse facets of the discipline. Through her active involvement in these conferences, Dr. Abid has not only contributed to the exchange of knowledge but also enriched her own understanding of zoology’s multifaceted dimensions.

Professional Profiles:

Publications Top Note:

1. Unlocking the potential of phenyl boronic acid functionalized-quercetin nanoparticles: Advancing antibacterial efficacy and diabetic wound healing

2. Revolutionizing Sericulture: Unleashing the Potential of Ascorbic Acid for Optimal Silkworm Well-being and Maximized Silk Production

3. Exploring the Potent Combination of Quercetināˆ’Boronic Acid, Epalrestat, and Urea Containing Nanoethosomal Keratolytic Gel for the Treatment of Diabetic Neuropathic Pain: In Vitro and In Vivo Studies

4.Survival, growth, behavior, hematology and serum biochemistry of mice under different concentrations of orally administered amorphous silica nanoparticle

5.Growth Response in Oryctolagus cuniculus to Selenium Toxicity Exposure Ameliorated with Vitamin E

Suresh Mickymaray | Nanobiotechnology | Best Researcher Award

Posted on by ScienceFather

Prof. Suresh Mickymaray: Nanobiotechnology: Best Researcher Award

Prof. Suresh Mickymaray, Majmaah University, Saudi Arabia

šŸ‘Øā€šŸ”¬ Prof. Suresh Mickymaray is an accomplished Associate Professor with over 25 years of expertise in Diagnostic Microbiology, Molecular Biology, and Clinical Microbiology. Currently serving as Associate Professor at Majmaah University, Saudi Arabia, he is also a Distinguished Adjunct Professor in Molecular Medicine and Diagnostics at Saveetha Dental College, India. Prof. Mickymaray’s extensive career includes roles as an Assistant Professor, Research Scholar, and Microbiologist. He excels in Clinical Diagnostic Microbiology, Molecular Biology, and Hospital Infection Control, showcasing a commitment to excellence in research, teaching, and administration. šŸ§ŖšŸ”¬

šŸ“… Career Overview:

Associate Professor: Microbiology, College of Science, Majmaah University, Saudi Arabia (Sep 2020 – Present). Distinguished Adjunct Professor: Centre of Molecular Medicine and Diagnostics, Saveetha University, India (Jan 2022 – Present). Assistant Professor: Microbiology, Majmaah University, Saudi Arabia (Jun 2016 – Aug 2020). Assistant Professor: Medical Laboratories, Majmaah University, Saudi Arabia (Aug 2014 – Jun 2016). Head: Microbiology & Molecular Biology, Doctors’ Diagnostic Center, Trichy, India (2012 – Aug 2014). Assistant Professor: Urumu Dhanalakshmi College, Trichy, India (Oct 2010 – Jan 2012). Research Scholar: A.V.V.M Sri Pushpam College, Thanjavur, India (Jun 2006 – Oct 2010). Microbiologist: Doctors’ Diagnostic Centre, Trichy, India (Apr 2004 – May 2006). Associate Microbiologist: Seahorse Hospitals Ltd., Trichy, India (1993 – Jun 2004).

šŸ† Accolades and Affiliations:

Ph.D. in Microbiology: Highly Commended, Bharathidasan University, Trichy. Diploma of Fellow Membership: Awarded by All India Institute of Medical Technologists, Kolkata. Member: Indian Initiative for Management of Antibiotic Resistance (IIMR).

šŸ§Ŗ Area of Expertise:

Clinical Microbiology and Molecular Biology: Diagnostic Molecular Biology of infectious diseases (Real-Time PCR). Clinical Mycology, Parasitology, and Virology. Routine and Special Microscopical examination for various pathogens. Culture, Identification, and susceptibility testing. Hospital Infection Control and Sterilization Procedures. Internal quality maintenance and biomedical instruments monitoring.

šŸŽ“ Educational Background:

Ph.D. in Microbiology: Immuno-Molecular Diagnosis of HIV/AIDS infections. M.Sc. in Microbiology: Demographic features and opportunistic infections in AIDS patients. B.Sc. in Zoology and Diploma in Medical Laboratory Technology (DMLT).

šŸ“ Global Contributions:

šŸ‡øšŸ‡¦ Saudi Arabia: Active involvement in academia and diagnostics at Majmaah University. šŸ‡®šŸ‡³ India: Distinguished Adjunct Professor at Saveetha University, Chennai.

šŸŒ International Recognition:

External Examiner: All India Institute of Medical Technologists, Kolkata.

Professional Profiles:

The impact of her research is evident in citation metrics and indices from Google Scholar:

  • Cited by: All ā€“ 1,046.
  • Citations ā€“ 938.
  • h-index ā€“ 15.
  • Documents ā€“ 39.

A prolific researcher making meaningful contributions to the academic world!

Research Focus: šŸ§¬

Prof. Suresh Mickymaray stands as a prominent figure in the scientific community, particularly excelling in the fields of Medicinal Nanoparticles and Antimicrobial Agents. His groundbreaking work includes the synthesis of gold nanoparticles from Catharanthus roseus, cited 377 times in 2019, demonstrating its potential in inducing caspase-mediated apoptosis in cervical cancer cells (HeLa). His impactful contributions extend to the exploration of flavonoids, with a focus on their anti-fungal efficacy and mechanisms, cited by 268 in 2020. Prof. Mickymaray’s research portfolio encompasses the evaluation of traditional medicinal plants and bioactive compounds against clinically important pathogens, earning 133 citations in 2019. In the realm of cancer research, his work on Rhaponticin’s suppression of osteosarcoma through the inhibition of the PI3K-Akt-mTOR pathway, cited 57 times in 2021, reflects his dedication to advancing therapeutic strategies against cancer. Prof. Suresh Mickymaray’s extensive contributions epitomize his commitment to advancing scientific knowledge for the betterment of healthcare. šŸŒšŸ”¬

Publications Top Note:

Prof. Funan Liu | Nanobiotechnology

Posted on by ScienceFather
Prof. Funan Liu: Oncolytic Virus

Congratulations, Prof. Funan Liu, on winning the esteemed Best Researcher Award from ScienceFather! Congratulations on reaching this significant milestone in your journey. Over the past year, you’ve undoubtedly achieved incredible feats and contributed immensely to your field. Here’s to many more years of success, innovation, and fulfillment in your endeavors. Wishing you continued growth, prosperity, and joy in the years to come. Keep shining and making a difference in the world!

Dr. Funan Liu is a distinguished medical professional, serving as a Professor, Chief Physician, and Doctoral Supervisor. Recognized as a key figure in healthcare, he holds prestigious positions as a Youth Top Talent under Liaoning Province’s ‘Revitalize Liaoning Talent Program’ and China Medical University’s Youth Top Talent. Additionally, he is a candidate in the ‘Hundred Thousand Ten Thousand Talent Project’ at the Thousand-Level. Dr. Liu serves as the Chief of the Phase I Clinical Trial Center at the First Affiliated Hospital of China Medical University. His expertise and leadership contribute significantly to advancing medical research and clinical trials, making him a prominent figure in the field.

Major academic positions:Ā Ā 

As the Deputy Director of the Gastric Cancer Committee for the Chinese Society for the Promotion of Health Science and Technology, Dr. Funan Liu plays a pivotal role in advancing gastric cancer research and awareness. He holds several leadership positions, including Vice Chairman of the 10th Committee of the Surgical Branch in the Liaoning Medical Association, and Standing Committee Member of various prestigious organizations, such as the Integrative Oncology Branch of the Chinese Anti-Cancer Association. Dr. Liu is actively involved in committees related to esophageal cancer, tumor prevention and control, oncology, and colorectal cancer. His extensive engagement underscores his commitment to multidisciplinary collaboration and advancing cancer care in various capacities within medical associations and committees.

Undertaken projects:

Dr. Funan Liu, a prominent researcher and medical professional, has spearheaded numerous groundbreaking projects in the realm of oncology. As a principal investigator, he led two National Key R&D Program research initiatives, focusing on clinical trials and therapeutic mechanisms of novel oncolytic virus cancer treatments, and the clinical evaluation of an in vitro tumor cell drug sensitivity technology system. Simultaneously, Dr. Liu undertook two National Natural Science Foundation of China general projects, investigating pH-sensitive liposome-hybrid red blood cell membrane-coated oncolytic virus intravenous delivery technology and the role of FN1 3ā€™UTR as a new ceRNA in gastric cancer. His comprehensive expertise extends to projects funded by Liaoning Province and the CSCO-Merck Serono Cancer Research Fund, solidifying his impactful contributions to advancing cancer research and treatment.

Hosted and participated in clinical research:

This extensive portfolio of clinical trials reflects a commitment to advancing medical science and improving patient outcomes across various oncological fronts. Driven by cutting-edge research, these trials span from Phase I to Phase III, covering a spectrum of investigational therapies for different types of advanced solid tumors. The studies explore innovative approaches such as immunotherapy combinations, targeted therapies, and novel agents, aiming to enhance treatment efficacy and patient survival. From evaluating the safety, tolerability, and pharmacokinetics of promising compounds like TIRAGOLUMAB and DN015089 to studying the potential benefits of combining checkpoint inhibitors with chemotherapy in gastric cancer (HLX10 trial), these trials address critical gaps in current cancer care.

The diversity of trials encompasses indications like breast cancer, colorectal cancer, gastric cancer, and more, reflecting a comprehensive strategy to combat a range of malignancies. The focus on specific genetic mutations, such as EGFR in cholangiocarcinoma and bladder cancer (AL8326 trial), underscores the importance of personalized medicine in tailoring treatments to individual patient profiles. Additionally, the exploration of novel agents like BC004 injection and TJ033721 reveals a dedication to identifying and developing innovative therapeutic modalities.

These studies not only aim to expand the armamentarium of available treatments but also contribute valuable insights to the evolving landscape of cancer research. By pushing the boundaries of scientific understanding, these clinical trials under the leadership of Dr. Funan Liu hold great promise in shaping the future of oncology and, ultimately, improving the lives of patients grappling with advanced solid tumors.

Professional Profiles:

The impact of her research is evident in citation metrics and indices from Google Scholar:

  • Cited by: All ā€“ 1,206.
  • Citations ā€“ 1,070.
  • h-index ā€“ 22.
  • Documents ā€“ 55.

A prolific researcher making meaningful contributions to the academic world!

Publications Top Note:
  1. Engineered bacterial outer membrane vesicles encapsulating oncolytic adenoviruses enhance the efficacy of cancer virotherapy by augmenting tumor cell autophagy
    • Published in Nature Communications in 2023 with 6 citations.
  2. Virus-Protein Corona Replacement Strategy to Improve the Antitumor Efficacy of Intravenously Injected Oncolytic Adenovirus
    • Published in ACS Nano in 2023 with 0 citations.
  3. Antigen-capturing oncolytic adenoviruses along with IDO blockade for improved tumor immunotherapy
  4. Inhibition of Tumor Metastasis by Liquid-Nitrogen-Shocked Tumor Cells with Oncolytic Viruses Infection
    • Published in Advanced Materials in 2023 with 4 citations.
  5. Oncolytic Virus-Driven Biotherapies from Bench to Bedside
    • Published in Small in 2023 with 2 citations.
  6. Self-assembled short peptides: Recent advances and strategies for potential pharmaceutical applications
    • Published in Materials Today in 2023 with 3 citations.
  7. Erythrocyte-Leveraged Oncolytic Virotherapy (ELeOVt): Oncolytic Virus Assembly on Erythrocyte Surface to Combat Pulmonary Metastasis and Alleviate Side Effects
    • Published in Advanced Science in 2023 with 0 citations.
  8. FN1 mRNA 3′-UTR supersedes traditional fibronectin 1 in facilitating the invasion and metastasis of gastric cancer through the FN1 3′-UTR-let-7i-5p-THBS1 axis
    • Published in Theranostics in 2023 with 0 citations.
  9. Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis
    • Published in Frontiers in Pharmacology in 2023 with 2 citations.
  10. Drug conjugate-based anticancer therapy – Current status and perspectives
    • Published in Cancer Letters in 2023 with 17 citations.